Journal of Cardiovascular Pharmacology

AUGUST 1, 2024

Thrombosis continues to pose a significant challenge in cardiovascular and cerebrovascular diseases, contributing to severe health complications such as myocardial infarction, acute ischemic stroke, and venous thromboembolism. In this paper, we comment the findings reported by Liu et al.

Cerebrovascular Disease 40

Cerebrovascular Disease Myocardial Infarction Thrombosis Strokes 40

DAIC

JANUARY 23, 2024

Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3

Cardiovascular Disease 111

Cardiovascular Disease Heart Attack Heart attacks Coronary Artery Disease 111

Frontiers in Cardiovascular Medicine

JANUARY 8, 2025

ObjectiveThis meta-analysis aims to evaluate the safety and efficacy of indobufen in the treatment of cardiovascular diseases, cerebrovascular diseases, and thromboembolic disorders. The primary focus is on the incidence of major adverse cardiovascular events (MACE), thrombosis, bleeding events, and adverse reactions.

Cerebrovascular Disease 52

Cerebrovascular Disease Cardiovascular Disease Myocardial Infarction Angina 52